Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Telos Corporation Q1 2026 Earnings Call - Revenue Surges 56% as New Business Pipeline Hits $500M
Telos Corporation kicked off 2026 with a sharp beat, reporting 56% year-over-year revenue growth to $47.7 million and adjusted EBITDA of $7.9 million, well above guidance. The company’s disciplined co...
- Revenue grew 56% year-over-year to $47.7 million, beating the high end of the $44M-$45M guidance range.
- Adjusted EBITDA reached $7.9 million, significantly exceeding the $4.5M-$5M guidance and marking a margin expansion from 1.2% to 16.5% year-over-year.
- Free cash flow margin held at 13.4% for the fifth consecutive quarter, demonstrating consistent cash generation and working capital discipline.
- +7 more takeaways
Shoals Technologies Group Q1 2026 Earnings Call - Record Backlog and Raised Guidance Drive Optimism
Shoals Technologies Group delivered a strong first quarter in 2026, with revenue surging 75% year-over-year to $141 million and adjusted EBITDA rising 56% to $21.1 million. The company set a new recor...
- Revenue surged 75% year-over-year to $141 million, beating guidance and reflecting strong demand in utility-scale solar.
- Record backlog and awarded orders (BLAO) reached $758 million, an 18% increase year-over-year, with $628 million slated for delivery through Q1 2027.
- Adjusted EBITDA grew 56% to $21.1 million, landing at the high end of guidance, while gross margin came in at 29.6%, slightly below expectations.
- +11 more takeaways
United Parks & Resorts Q1 2026 Earnings Call - Weather Woes Mask Strong Per Cap Growth and Aggressive Buybacks
United Parks & Resorts reported a disappointing first quarter, with revenue falling 3.1% year-over-year to $278.3 million and adjusted EBITDA declining 14% to $58 million. The shortfall was driven by ...
- Revenue dropped 3.1% to $278.3 million and adjusted EBITDA fell 14% to $58 million, primarily due to a 171,000-guest attendance decline caused by severe weather and weak international travel.
- Underlying demand held up: adjusted for weather and international headwinds, attendance grew over 1%, and in-park per capita spending surged 5.3% to a record $40.62.
- Management flagged a 220,000-guest drag on attendance, with 140,000 guests lost to weather and 80,000 to declining international visitation driven by geopolitical dynamics.
- +7 more takeaways
SharpLink Q1 2026 Earnings Call - Compounding ETH per Share Through Disciplined Yield and Strategic Partnerships
SharpLink reported a revenue surge to $12.1 million for Q1 2026, driven by its staking strategy, but faced a $685.6 million net loss due to a $191.7 million impairment charge and a $506.7 million unre...
- SharpLink held approximately 872,984 ETH as of May 4, 2026, with a combined fair value of over $1.2 billion in native ETH and $487 million in liquid staked tokens as of Q1.
- Revenue surged to $12.1 million in Q1 2026 from $0.7 million in the prior year, primarily due to the success of the ETH staking strategy, including a $200 million deployment on Linea Layer 2.
- The company reported a net loss of $685.6 million for Q1 2026, driven by a $191.7 million impairment charge and a $506.7 million unrealized loss, though management stressed these reflect accounting rules rather than realized economic losses.
- +7 more takeaways
Great Elm Capital Corp Q1 2026 Earnings Call - NAV Protection Takes Precedence Over Income Growth
Great Elm Capital Corp's first quarter 2026 earnings call marks a strategic pivot under new CEO Jason Reese. The company is explicitly prioritizing NAV protection and capital preservation over income ...
- Strategic Pivot to NAV Protection: CEO Jason Reese has reprioritized the company's mandate, placing NAV protection and capital preservation ahead of income generation following recent unrealized losses.
- Incentive Fee Waivers Continue: Great Elm Capital Management waived all accrued and unpaid incentive fees through June 30, 2026, providing a $0.20 per share direct benefit to shareholders and marking the third consecutive quarter of waivers.
- Aggressive Deleveraging: The company called and repurchased $57.5 million in GECCO notes, eliminating near-term debt maturities until 2029 and removing refinancing risk from the balance sheet.
- +7 more takeaways
Pediatrix Medical Group Q1 2026 Earnings Call - Strong Pricing Drives EBITDA Beat Despite Volume Headwinds
Pediatrix Medical Group delivered a robust first quarter, with adjusted EBITDA reaching $58 million, significantly outpacing expectations. The growth was fueled by a 4% pricing increase, which more th...
- Adjusted EBITDA reached $58 million in Q1 2026, driven by top-line growth that outpaced volume declines.
- Pricing increased by 4%, fueled by strong RCM cash collections, favorable payer mix, higher patient acuity, and increased contract administrative fees.
- Same-unit volumes declined slightly by just under 3%, with NICU days down approximately 1%, though management sees no sustained negative trend.
- +9 more takeaways
Progressive Corporation Q1 2026 Earnings Call - Aggressive Share Acquisition Fuels Record Growth Amidst Industry Soft Market
Progressive is aggressively capturing market share in a highly competitive personal auto landscape, adding nearly $9 billion in new written premiums in 2025 alone. Management is prioritizing policy gr...
- Progressive captured 86% of the total personal auto written premium growth among the top 10 carriers in 2025, adding $8.9 billion to a market expansion of $11.8 billion.
- The company increased Q1 2026 media spend by 20% year-over-year, marking the highest quarterly advertising investment in company history to fuel new business acquisition.
- Management is actively targeting the Robinson segment, representing a $40 billion to $50 billion top-line opportunity, with plans to double market penetration from 20% to 40%.
- +7 more takeaways
FS KKR Capital Corp Q1 2026 Earnings Call - KKR Launches $600M Support Package Amid NAV Decline
FS KKR Capital Corp reported a challenging first quarter of 2026, with its net asset value per share declining 9.9% to $18.83, driven by permanent impairments in legacy software and service names, new...
- FSK's NAV per share declined 9.9% to $18.83, with the drop attributed to permanent impairments in specific portfolio companies, new non-accrual investments, and mark-to-market moves across software and services names.
- Net investment income remained stable at $0.42 per share, leading the board to declare a consistent second quarter distribution of $0.42 per share, aligning with the policy of paying 100% of GAAP net investment income.
- KKR is executing a $600 million support package comprising a $150 million fixed-price tender offer at $11 per share, a $150 million convertible preferred investment, a $300 million share repurchase authorization, and a four-quarter fee waiver.
- +7 more takeaways
Alkami Technologies Q1 2026 Earnings Call - Strong Growth, DSSP Momentum, and AI Monetization in Focus
Alkami Technologies delivered a robust Q1 2026, with revenue jumping 29% to $126.1 million and adjusted EBITDA surpassing expectations at $22.3 million. The company closed six new digital banking rela...
- Revenue surged 29% year-over-year to $126.1 million, beating management expectations and signaling strong demand for Alkami’s digital banking solutions.
- Adjusted EBITDA reached $22.3 million, significantly above the high end of guidance, demonstrating improved operating leverage and cost discipline.
- The company closed six new digital banking logos in Q1, including two banks and three Digital Sales & Service Platform (DSSP) clients, highlighting successful market penetration.
- +7 more takeaways
Certara Q1 2026 Earnings Call - Exiting Medical Writing, Betting Big on AI-Integrated MIDD Platform
Certara reported a solid start to 2026, with software revenue growing 7% and software bookings jumping 20%, driven by strong demand across all customer tiers. The company exited its medical and regula...
- Certara exited its medical and regulatory writing business to Veristat, a move designed to sharpen focus on high-margin, tech-enabled drug development and improve revenue predictability.
- Software revenue grew 7% year-over-year to $49.7 million, with software bookings surging 20% to $48.7 million, driven by broad-based strength across all customer tiers.
- Management reorganized the company into two core growth areas: MID3 (Model-Informed Drug Development) and ACE (Accelerated Clinical Evidence), aiming to create a tighter flywheel between technology and expert services.
- +7 more takeaways